US FDA decision date on camizestrant extended

AI SummaryClose X

AstraZeneca has announced that the US FDA has extended the review date for camizestrant in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations, to allow for the review of additional data. This decision follows a non-majority vote from the FDA's Oncologic Drugs Advisory Committee regarding the drug's benefit in specific patient scenarios. The company has provided further analyses, including ctDNA clearance data linked to long-term efficacy, which will be presented at ASCO 2026. This news comes as the European Medicines Agency's Committee for Medicinal Products for Human Use recently adopted a positive opinion recommending approval for the same indication.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings